Carboxypeptidase E mRNA: Overexpression predicts recurrence and death in lung adenocarcinoma cancer patients
Autor: | Danping Liu, Yi Ching Wang, I-Ying Kuo, Wu Wei Lai, Y Peng Loh |
---|---|
Rok vydání: | 2022 |
Předmět: |
Oncology
Cancer Research medicine.medical_specialty Lung Neoplasms viruses Cell Adenocarcinoma of Lung Adenocarcinoma stomatognathic system Internal medicine Genetics medicine Humans RNA Messenger Lung cancer Survival analysis Lung biology business.industry Carboxypeptidase H Cancer General Medicine biochemical phenomena metabolism and nutrition Prognosis medicine.disease medicine.anatomical_structure Carboxypeptidase E biology.protein Biomarker (medicine) business |
Zdroj: | Cancer Biomarkers. 33:369-377 |
ISSN: | 1875-8592 1574-0153 |
Popis: | BACKGROUND: Effective biomarkers for prediction of recurrence of lung adenocarcinoma cancer (LADC) patients are needed to determine treatment strategies post-surgery to improve outcome. OBJECTIVE: This study evaluates the efficacy of carboxypeptidase E (CPE) mRNA including its splice isoforms, CPE-ΔN, as a biomarker for predicting recurrence in adenocarcinoma patients. METHODS: RNA was extracted from resected tumors from 86 patients with different stages of non-small cell LADC. cDNA was synthesized and qRT-PCR carried out to determine the copy numbers of CPE/CPE-ΔN mRNA. Patients were followed for 7 years post-tumor resection to determine recurrence and death. RESULTS: ROC curve analysis showed the overall AUC for CPE/CPE-ΔN copy number was 0.563 in predicting recurrence and 0.562 in predicting death. Kaplan-Meier survival analysis showed statistical difference (p= 0.018), indicating that patients with high CPE/CPE-ΔN copy numbers had a shorter time of disease-free survival and also shorter time to death (p= 0.035). Subgroup analyses showed that association of disease-free survival time with CPE/CPE-ΔN copy number was stronger among stage I and II LADC patients (p= 0.047). CONCLUSIONS: CPE/CPE-ΔN mRNA is a potentially useful biomarker for predicting recurrence and death in LADC patients, especially in identifying patients at high risk of recurrence at early stages I and II. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |